Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamza Hashmi

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Blood Advances|August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myelomaJennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood Advances|August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell LeukemiaGliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Transplantation and Cellular Therapy|April 27, 2025
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell LymphomaRoni Shouval, Christopher Strouse, Soyoung Kim, et al.
Blood|April 21, 2025
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell TherapyKai Rejeski, Jaime Sanz, Teng Fei, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Blood Advances|August 14, 2025
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell LymphomaUri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
The New England Journal of Medicine|June 6, 2022
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G Richardson, Susanna J Jacobus, Edie A Weller, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Blood Advances|August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myelomaJennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood Advances|August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell LeukemiaGliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Transplantation and Cellular Therapy|April 27, 2025
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell LymphomaRoni Shouval, Christopher Strouse, Soyoung Kim, et al.
Blood|April 21, 2025
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell TherapyKai Rejeski, Jaime Sanz, Teng Fei, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Blood Advances|August 14, 2025
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell LymphomaUri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
The New England Journal of Medicine|June 6, 2022
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G Richardson, Susanna J Jacobus, Edie A Weller, et al.
Pageof 10